Treating T3 Deficiency, The Evidence You Need – Part 9

Objectives | Instructor| Enrollment Options | Accreditation

Objectives

Upon completion of this workshop, the healthcare professional will be able to:

1. While hyperthyroidism is a significant cardiovascular risk factor causing 20% premature death rate, participants will identify how HDT treatment does not appear to be a significant cardiovascular risk.
2. Interpret the myths of HDT risk factors, the first being that HDT can increase the risk of developing osteoporosis and the second is that it increases cardiovascular risk.
3. Recognize the cardiovascular risks of HDT appear to be low. HDT is at least as safe as or safer than many psychiatric medications.
4. Recall how the chronic misuse of terminology in literature (i.e. calling all suppressed TSH or elevations of thyroid hormone to mean hyperthyroidism) are at best confusing in determining the difference between HDT and hyperthyroidism.

Instructor

Neal Rouzier, MD

Faculty Chairman

Accreditation

In support of improving patient care, this activity has been planned and implemented by The Foundation for Care Management (FCM) and Worldlink Medical.  FCM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This program is approved for 1.0 AMA Category 1 Credits.

This program is approved for 1.0 Nursing Contact hour of Education.

Enrollment Options

Enroll today with a Premium Membership for $495/year, for access to THIS course and:

• All 1 Hour Accredited Courses (28+ more added monthly)
• All upcoming Accredited Monthly Webinars
• All upcoming Journal Clubs AND Journal Club Library
• EBSCOhost – research articles for the BHRT Workshop Series and to support your own evidence based studies!

Upgrade Membership